Antipsychotic efficacy measured by real-world observational study

telescope-1082091_640

Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things

photo-1436124396594-54d90bf69c66

Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Prescribing antipsychotics in primary care: new study highlights frequent off-label use

shutterstock_146973512

Josephine Neale reports on a recent cohort study that finds less than half of UK prescriptions for antipsychotics are issued for main licensed conditions (e.g. psychosis or bipolar disorder). The research provides a reminder about the dangers of prescribing antipsychotics to people with dementia.

[read the full story...]

Efficacy of high vs. low-potency first-generation antipsychotics for schizophrenia

Screen Shot 2014-10-03 at 13.24.52

Laurence Palfreyman summarises 3 recent Cochrane reviews, which investigate high-potency versus low-potency first-generation antipsychotic drugs for schizophrenia. The reviews find little difference in efficacy between the high-potency antipsychotics Trifluoperazine, Haloperidol, Fluphenazine, and low-potency typical antipsychotics.

[read the full story...]

Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects

Antipsychotic medication is the standard treatment for schizophrenia and psychosis in the UK.  Given that psychosis is commonly a chronic condition and therefore that medication used to treat it often needs to be taken for several years, getting the medication “right” is important. As I mentioned in my first blog post for the Mental Elf, [read the full story…]

German cohort study finds no support for superiority of atypical antipsychotics in schizophrenia

It is possible that those who were disengaging from interventions such as medication were less likely to take part in the study.

Schizophrenia according to the NICE guidelines, is a relatively common illness and in the majority of cases takes a chronic course, requiring continued management and careful attention.  In the treatment and management of schizophrenia, antipsychotic medications – like olanzapine, quetiapine or clozapine – are the first line intervention. Antipsychotics can be loosely divided into “first-generation” (“typical”) and [read the full story…]